Weekly Investment Analysts’ Ratings Changes for Inventiva (IVA)

A number of research firms have changed their ratings and price targets for Inventiva (NASDAQ: IVA):

• 11/18/2025 – Inventiva had its price target lowered by analysts at Guggenheim from $13.00 to $11.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Inventiva was upgraded by analysts at Wolfe Research to a “strong-buy” rating.
• 11/5/2025 – Inventiva is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $13.00 price target on the stock.
• 11/5/2025 – Inventiva is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $13.00 price target on the stock.
• 10/18/2025 – Inventiva was upgraded by analysts at Wall Street Zen to a “hold” rating.
• 10/9/2025 – Inventiva had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Inventiva had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/30/2025 – Inventiva had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $20.00 price target on the stock.
• 9/27/2025 – Inventiva had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.